Table 3. Infection-Related Outcomes... | American Society of Hematology

Table 3.

Infection-Related Outcomes During First Hospitalization for Elderly AML Patients

End Points	Placebo Median (range) (n = 104)	G-CSF Median (range) (n = 103)	One-Tailed P Value^*
No. of days with fever	10 (0-34)	8 (0-79)	.091
No. of days on IV antibiotics	26 (0-69)	22 (0-128)	.053
	No. of Patients (%)	No. of Patients (%)
No. of culture confirmed infections^†
0	37 (36%)	28 (27%)
1	23 (22%)	29 (28%)
2	21 (20%)	24 (23%)
3 or more	22 (21%)	22 (21%)	.82

Fungal infection^‡	16 (15%)	21 (20%)	.87
Amphotericin-B given	61 (59%)	61 (59%)	.59
Pneumonia present	25 (24%)	33 (32%)	.93
Positive blood culture	45 (43%)	50 (49%)	.82
No. of fatal infections	14 (14%)	20 (19%)	.90

End Points	Placebo Median (range) (n = 104)	G-CSF Median (range) (n = 103)	One-Tailed P Value^*
No. of days with fever	10 (0-34)	8 (0-79)	.091
No. of days on IV antibiotics	26 (0-69)	22 (0-128)	.053
	No. of Patients (%)	No. of Patients (%)
No. of culture confirmed infections^†
0	37 (36%)	28 (27%)
1	23 (22%)	29 (28%)
2	21 (20%)	24 (23%)
3 or more	22 (21%)	22 (21%)	.82

Fungal infection^‡	16 (15%)	21 (20%)	.87
Amphotericin-B given	61 (59%)	61 (59%)	.59
Pneumonia present	25 (24%)	33 (32%)	.93
Positive blood culture	45 (43%)	50 (49%)	.82
No. of fatal infections	14 (14%)	20 (19%)	.90

*One-tailed tests of significance of the beneficial effect of G-CSF on these outcomes.

Includes all culture confirmed infections, including oral thrush and herpes viral infection.

Only invasive fungal infections; excludes thrush.